Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 Edotreotide - Isotopen Technologien Munchens

Next Previous
Drug Profile

Gallium-68 Edotreotide - Isotopen Technologien Munchens

Alternative Names: 68Ga-Edotreotide; Gallium-68-DOTATOC; Lutetium-177 labelled edotreotide companion diagnostic; Sogacin; TOCscan

Latest Information Update: 29 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isotopen Technologien Munchens
  • Class Cyclic peptides; Imaging agents; Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroendocrine tumours

Most Recent Events

  • 27 Dec 2021 ITM Medical Isotopes GmbH enters an licensing agreement with Grand Pharmaceutical for Gallium-68 edotreotide in mainland China, Hong Kong, Macau and Taiwan
  • 19 Jul 2019 Launched for Neuroendocrine tumours (Diagnosis) in Germany before July 2019 (Parenteral), France before July 2019 (Parenteral), Austria (Parenteral) before July 2019 (Isotopen Technologien Munchen pipeline July 2019)
  • 28 May 2018 Registered for Neuroendocrine tumours (Diagnosis) in France (Parenteral), Germany (Parenteral), Austria (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top